Get the Stockscreener App
5.42
0.91%
-0.05
Pre-market:
5.81
0.39
+7.20%
Candel Therapeutics Inc stock is traded at $5.42, with a volume of 753.40K.
It is down -0.91% in the last 24 hours and up +14.47% over the past month.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$5.47
Open:
$5.34
24h Volume:
753.40K
Relative Volume:
0.70
Market Cap:
$271.54M
Revenue:
$124.00K
Net Income/Loss:
$-49.99M
P/E Ratio:
-3.2071
EPS:
-1.69
Net Cash Flow:
$-31.03M
1W Performance:
+6.07%
1M Performance:
+14.47%
6M Performance:
+7.54%
1Y Performance:
-48.77%
1-Day Range:
$5.31
$5.65
1-Week Range:
$5.09
$5.935
52-Week Range:
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
5.42 | 256.02M | 124.00K | -49.99M | -31.03M | -1.69 |
|
ONC
Beigene Ltd Adr
|
238.76 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.03 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.85 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.69 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-25 | Initiated | Citigroup | Buy |
| Feb-19-25 | Initiated | Canaccord Genuity | Buy |
| Feb-07-25 | Initiated | BofA Securities | Buy |
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
View All
Candel Therapeutics Inc Stock (CADL) Latest News
Candel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025 - Yahoo Finance
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 - GlobeNewswire
Breakthrough Phase 3 Results: First Successful Prostate Cancer Trial in 20 Years Shows 30% Lower Recurrence Risk - Stock Titan
Best Momentum Stocks to Buy for May 19th - The Globe and Mail
New Strong Buy Stocks for May 19th - The Globe and Mail
Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know - MSN
CADL To Present Prostate Cancer Trial Data, RMD's Q3 Revenue Climbs 8%, AUNA On Watch... - RTTNews
Promising Pipeline Developments and Strong Data Support Buy Rating for Candel Therapeutics - TipRanks
Candel Therapeutics Reports Strong Q1 2025 Results - TipRanks
CADL's Cash Reserves Projected to Last Until Early 2027 | CADL S - GuruFocus
Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish - NewsBreak: Local News & Alerts
Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish By Stocktwits - Investing.com India
Small cap wrap: Candel Therapeutics, Nevis Brands, Fineqia, Voyageur Pharmaceuticals, atai... - Proactive Investors
Candel Therapeutics (CADL) Reports Q1 Earnings and Cash Reserves - GuruFocus
Market movers: Coinbase, Hertz, Candel Therapeutics, JD Sports... - Proactive Investors
Cardell Flat on Q1 - Baystreet.ca
Candel Therapeutics posts Q1 profit, eyes 2026 BLA submission for prostate cancer drug - Proactive financial news
Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - ADVFN
Candel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Wells Fargo & Company MN Increases Stake in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Barclays PLC Purchases 5,629 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Candel Therapeutics (CADL) Expected to Announce Earnings on Tuesday - Defense World
Candel Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
Candel Therapeutics (NASDAQ:CADL) vs. Calidi Biotherapeutics (NYSE:CLDI) Critical Review - Defense World
Candel Therapeutics to present at upcoming healthcare conferences - Proactive financial news
Candel Therapeutics to Present at Upcoming Investor Conferences in May and June 2025 - Nasdaq
Candel Therapeutics Inc [CADL] stock for 396,995 USD was sold by Nichols William Garrett - knoxdaily.com
Is Candel Therapeutics Inc (CADL) worth investing in despite its overvalued state? - uspostnews.com
LPL Financial LLC Makes New Investment in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Financial Metrics Check: Candel Therapeutics Inc (CADL)’s Ratios for Trailing Twelve Months - DWinneX
Geode Capital Management LLC Grows Stock Position in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
S3e01 Life Changing Innovation with Paul Peter Tak, CEO of Candel Therapeutics - iHeart
A new trading data show Candel Therapeutics Inc (CADL) is showing positive returns. - Sete News
Candel Therapeutics to Present Prostate Cancer Trial Data By Investing.com - Investing.com South Africa
Candel Therapeutics to Present Prostate Cancer Trial Data - Investing.com
Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 - The Manila Times
Candel Therapeutics Announces Oral Presentation of CAN-2409 Data at 2025 ASCO Annual Meeting - Nasdaq
Candel Therapeutics Announces Oral Presentation of Positive - GlobeNewswire
Major Phase 3 Trial Results: Breakthrough Prostate Cancer Treatment Data to be Revealed at ASCO 2025 - Stock Titan
Candel Therapeutics to present Phase 3 prostate cancer data at 2025 ASCO Annual Meeting - Proactive Investors
Technical analysis of Candel Therapeutics Inc (CADL) stock chart patterns - uspostnews.com
How To Trade (CADL) - news.stocktradersdaily.com
Candel Therapeutics (NASDAQ:CADL) Earns “Buy” Rating from HC Wainwright - Defense World
Critical Review: Candel Therapeutics (NASDAQ:CADL) & ProKidney (NASDAQ:PROK) - Defense World
H.C. Wainwright maintains Buy on Candel Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains Buy on Candel Therapeutics stock - Investing.com Australia
Private Sector Steps Up in Cancer Research as Federal Support Wavers - Baystreet.ca
Candel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409 - Proactive financial news
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
6.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):